Gyre Therapeutics (NASDAQ:GYRE) Shares Up 1.4% - What's Next?

Key Points

• Gyre Therapeutics' stock increased by 1.4% on Wednesday, trading at $7.02 with a market cap of $658.20 million and a P/E ratio of 351.18.
• The company reported quarterly earnings of $0.03 EPS on revenue of $22.06 million, which fell short of the consensus estimate of $28.40 million.
• Significant hedge fund activity includes Wells Fargo and Bank of America increasing their stakes, contributing to 23.99% of the stock being owned by institutional investors.

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report)'s stock price was up 1.4% on Wednesday . The stock traded as high as $7.06 and last traded at $7.02. Approximately 77,301 shares were traded during trading, a decline of 0% from the average daily volume of 77,415 shares. The stock had previously closed at $6.92.

Gyre Therapeutics Trading Down 0.1%

The firm has a fifty day moving average of $7.69 and a 200 day moving average of $9.25. The company has a market capitalization of $674.13 million, a P/E ratio of 359.68 and a beta of 1.80.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.03. Gyre Therapeutics had a return on equity of 9.73% and a net margin of 7.20%. The business had revenue of $22.06 million during the quarter, compared to the consensus estimate of $28.40 million.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in GYRE. Barclays PLC lifted its holdings in Gyre Therapeutics by 13.5% in the 4th quarter. Barclays PLC now owns 10,543 shares of the company's stock worth $128,000 after purchasing an additional 1,255 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Gyre Therapeutics by 15,083.3% during the 1st quarter. GAMMA Investing LLC now owns 1,822 shares of the company's stock worth $140,000 after acquiring an additional 1,810 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Gyre Therapeutics by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock worth $49,000 after acquiring an additional 913 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Gyre Therapeutics by 18.7% during the 1st quarter. Bank of New York Mellon Corp now owns 16,492 shares of the company's stock worth $127,000 after acquiring an additional 2,596 shares in the last quarter. Finally, SBI Securities Co. Ltd. increased its position in shares of Gyre Therapeutics by 22.1% during the 1st quarter. SBI Securities Co. Ltd. now owns 123,629 shares of the company's stock valued at $954,000 after purchasing an additional 22,390 shares during the last quarter. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.